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SIGNIFICANCE
The effect of herring roe oil capsules was tested in patients 
with psoriasis. This study demonstrates a positive effect on 
psoriasis. Disease severity is important when determining 
the appropriate treatment of psoriasis patients. In recent 
years, several new drugs have become available for the 
treatment of severe psoriasis whereas there have been few 
treatment advances for patients with milder psoriasis. This 
study demonstrates promise for herring roe oil as a safe 
treatment option in patients with non-severe psoriasis.
The effect of omega-3 polyunsaturated fatty acid 
supplements in patients with psoriasis vulgaris has 
previously been investigated, but interventions varied 
in source, composition, dose, administration route and 
duration of treatment. The observed beneficial effects 
in patients with psoriasis vulgaris using herring roe oil 
as a dietary supplement prompted this investigation. 
This randomised, double-blind and placebo-controlled 
study was designed and performed to explore the ef-
ficacy and safety of herring roe oil supplementation in 
64 patients with plaque psoriasis (ClinicalTrials.gov: 
NCT03359577). The primary end-point was compa-
ring the change in mean Psoriasis Area Severity Index 
(PASI) scores in the herring roe oil treatment group 
and the placebo group from baseline to week 26. In the 
intention-to-treat population, a statistically significant 
improvement in the mean PASI score was observed 
with herring roe oil compared to placebo at 26 weeks. 
In the recruited patient group, the measured impro-
vement was greatest in patients with a PASI score 
from 5.5–9.9 at baseline. 
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Psoriasis can be divided into mild, moderate or se-vere psoriasis based on the extent of body surface 
area (BSA) covered by psoriasis (1), and into mild and 
moderate to severe based on Psoriasis Area Severity 
Index (PASI). For the treatment of patients with a PASI 
score above 10, a growing armamentarium of systemic 
biological medicines has become available during the 
past decade. For patients with psoriasis with BSA< 10% 
and/or PASI < 10 there have been few treatment advances 
in recent years. 
Several studies have investigated the effects of 
omega-3 fatty acids in the treatment of psoriasis (2–4). 
A systematic review by Upala et al. (5) stated that no 
conclusions could be drawn regarding the use of n-3 
polyunsaturated fatty acids (PUFAs) and improvement 
in psoriasis. This review found 12 eligible clinical stu-
dies where ω-3 PUFA interventions varied in source, 
composition, dose, administration route and duration of 
treatment. In 10 out of the 12 reviewed studies, treat-
ment duration was shorter than 26 weeks. The ratio of 
eicosapentaenoic acid (EPA) to docosahexaenoic acid 
(DHA) was typically 1:1, or contained more EPA than 
DHA (5).
One major difference between herring roe oil (HRO)
and the ω-3 PUFAs from fish oils is the natural DHA to 
EPA ratio, which is approximately 3:1 in herring roe. 
EPA has been found to cause a switch in production of 
eicosanoids from proinflammatory prostaglandins and 
leukotrienes in the 2 and 4 series, respectively, to the less 
inflammatory 3 and 5 series (6). In addition, DHA is me-
tabolized to Specialized Pro-Resolving Lipid Mediators 
(protectins, resolvins and maresins) which reduce inflam-
matory processes (7). In herring roe, approximately two 
thirds of the fatty acids are esterified to phospholipids, 
including phosphatidylcholine. DHA and EPA found in 
triglyceride lowering medicines are typically bound to 
an ethyl group (Omacor®) or they are free fatty acids 
(Epanova®). These differences may especially affect the 
bioavailability of DHA and EPA (8, 9). 
In this clinical study, the efficacy of capsulated HRO 
was investigated in psoriasis patients with PASI < 10. We 
postulated that the effect of this composition differs from 
fish oils previously tested in clinical studies of patients 
with psoriasis.
MATERIALS AND METHODS
Subjects and study design
Sixty-four patients with stable, plaque psoriasis were recruited at 
the Department of Dermatology, Haukeland University Hospital, 
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Bergen, Norway. The patients were enrolled in a randomized, 
26-weeks, single-centre, placebo-controlled, double-blind study 
to investigate the effects of a dietary supplement containing 
HRO. The study was approved by the Regional Committees for 
Medical and Health Research Ethics in western Norway (REK 
Vest, 2017/938). 
Patients consented to participate in writing. Eligible patients 
were block randomized using randomly selected block sizes, strati-
fied according to sex, and assigned to either HRO or to the control 
group (Coconut oil). In both groups, patients received 10 capsules 
daily, 5 in the morning and five in the evening in conjunction with 
a meal. Remaining capsules were counted at clinic visits.
Patients with stable psoriasis for 6 months and with PASI scores 
less than 10 were eligible to be included in the study. Patients on 
stable local anti-psoriatic maintenance treatment for more than two 
months before study start continued this treatment. There were no 
limitations on the use of unmedicated moisturising creams during 
the study. Patient demographics and numbers of patients using 
local steroid treatment are shown in Table I.
Herring roe oil capsules
Each HRO capsule contained 292 mg poly-unsaturated fatty acids 
(total ω-3): 22 % eicosapentaenoic acid (EPA, 20:5 ω-3) and 66 % 
docosahexaenoic acid (DHA, 22:6 ω-3), where approximately 35% 
of both was bound to phospholipids, including phosphatidylcho-
line. The total daily dose of EPA and DHA was 2.6 g and the total 
lipid dose was 5.9 g. Each placebo capsule contained medium 
chain triglycerides: Coconut oil high in caprylic acid (C8:0) and 
capric acid (C10:0). The same type 590 mg softgel capsule was 
filled with active substance or placebo.
Clinical examinations
Clinical examinations were performed at screening, baseline and 
at weeks 6, 12, 18 and 26. Standardised scoring tools in psoriasis 
were used to assess the severity of psoriasis i.e. PASI (10, 11), 
Physician’s Static Global Assessment (PSGA) (11), and BSA (1).
Patient reported data 
Dermatological Life Quality Index (DLQI) (12) and Visual Ana-
logue Scale (VAS) scores were used to measure: itching, pain 
(skin/joints), singeing and general health conditions (general/
skin). Bi-weekly, questionnaires concerning compliance, number 
of fish meals, number of alcohol units, use of rescue medication 
(local steroids), intake of sugar, exercise and adverse events were 
completed by participants.
Dietary requirements 
Patients were instructed to discontinue any supplements of cod li-
ver oil, ω-3 and choline for 4 weeks prior to study commencement. 
Vitamin D, ω-3 and choline supplements were prohibited during 
the study. Patients were asked not to change their diet including 
keeping their usual intake of fish in the diet, and to refrain from 
excessive alcohol intake. 
Laboratory analyses 
All serum, plasma and full-blood samples were aliquoted and 
kept in a locked –80°C freezer until all analyses were performed. 
Analyses were performed using the same controls and procedu-
res as those routinely used at the hospital laboratory. Levels of 
pro-inflammatory cytokines and C-reactive protein (CRP) were 
measured. 
Cytokines were measured using a panel of magnetic beads for 
the detection of 16 cytokine analytes (IFN-γ, IL-1α, IL-1β, IL-1ra, 
IL-2, IL-6, IL-10, IL-12p70, IL-17A, IL-21, IL-22, IL-23, IL-33, 
TNF-α, VEGF-A, VEGF-D). The panel was obtained from R&D 
systems (McKinley, MN, USA). The assay was performed as 
recommended by the manufacturer, and Luminex 100 (Luminex 
Corp., Austin, TX, USA) and STarStation Software v.3.0 (Applied 
Cytometry System, Dinnington, UK) was used for recording and 
analysing the data.
Statistical analysis
The primary variable was the change from baseline to week 26 in 
PASI in the HRO group as compared to placebo. The intention-
to-treat (ITT) population was used for calculations. ITT was 
defined as randomised patients who received at least one dose 
of study treatment. For subjects discontinuing the study before 
week 26, the last observation was imputed as the week 26 value. 
The primary end-point was analysed by analysis of covariance 
(ANCOVA). The change in PASI score from baseline to week 26 
was modelled as a function of treatment group and baseline PASI 
score. A significance level of 5% was used in two-tailed tests. 
Treatment group and baseline PASI score were kept in the model 
regardless of p-values, other covariates i.e. sex and age were kept 
if significant on a 5% level. 
RESULTS 
Patient attendance
In the HRO group, 3 patients discontinued the study. One 
patient withdrew due to an adverse event (gastritis), one 
patient withdrew at 6 weeks due to unsatisfying response 
and one was lost to follow-up. All patients in the placebo 
group completed the study (Fig. 1).
Efficacy 
Baseline characteristics of the study groups were com-
parable (Tables I and II). Mean DLQI, PASI, BSA, 
PSGA and CRP at baseline (week 0) and at week 26 
are displayed in Table II. Patients included had baseline 
PASI scores between 3.4 and 9.9. The mean baseline 
CRP in the HRO group was higher than in the placebo 
group and the standard deviation was large due to 3 
patients with elevated CRP concentrations at 17, 26 and 
68 mg/l. Baseline PASI scores in the same patients were 
3.7, 5.5 and 4.9. 
There was a statistically significant improvement in 
the mean PASI score with HRO treatment compared to 
Table I. Patient demographics
Parameter HRO Placebo Total
Subjects, n 32 32 64
  Male, n (%) 17 (53.1) 19 (59.4) 36 (56.3)
  Female, n (%) 15 (46.9) 13 (40.6) 28 (43.8)
Age at informed consent, years, 
mean (SD)
47.0 (12.8) 51.0 (14.2) 49.0 (13.6)
Height, cm, mean (SD) 174.6 (8.8) 174.6 (12.3) 174.6 (10.6)
Body weight, kg, mean (SD) 89.8 (17.9) 88.4 (20.8) 89.1 (19.2)
BMI, kg/m2, mean (SD) 29.54 (5.80) 28.61 (3.81) 29.07 (4.89)
Subjects using local steroids during 
study, n (%)
18 (56) 16 (50) 34 (53)
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placebo treatment with a mean change in PASI score 
estimated to –1.1 with a 95% confidence interval < –2.2, 
–0.025>, p = 0.0451. The photograph displays one patient 
in the active treatment group at week 26 (Fig. 2, PASI: 
0.7, Baseline: PASI 9.5).
There were no statistically significant beneficial ef-
fects of treatment compared to placebo in analyses of 
variables such as PASI 50, PSGA, DLQI, BSA or VAS 
scores (data not shown) during the course of the study.
A panel of cytokines (IFN-ƴ, IL-1α, IL-1ra, IL-1β, 
IL-2, IL-6, IL-10, IL-12p70, IL-17A, IL-21, IL-22, IL-
23, IL-33, TNF-α, VEGF-A, VEGF-D) was measured in 
plasma at week 0, 12 and 26. Generally, measured cyto-
kine concentrations at baseline were low in the majority 
of patients in both study groups which is as expected in 
patients with mild disease (data not shown). Although 
certain cytokines dropped significantly in the active 
treatment group (IFN-γ, IL-6, IL-21, IL-22, IL-23, IL-
33) from baseline to week 26, no statistically significant 
differences were observed when comparing changes of 
cytokines in the active treatment group with changes in 
the placebo group.
Post-hoc analyses
The ITT population was split into halves of low and high 
baseline PASI scores, separated at the median score of 5.5 
and the difference in mean PASI scores between study 
groups were compared at week 26. In the patients with 
baseline PASI ≤ 5.5, the treatment difference between 
HRO and placebo in terms of PASI score was estimated 
to –0.005 with a 95% confidence interval < –1.2, 1.2>, 
p = 0.99, indicating no difference between HRO treatment 
and placebo. However, in the subjects with baseline PASI 
> 5.5, the mean treatment difference between HRO and 
placebo in PASI score was estimated to –2.4 with a 95% 
confidence interval <–4.3, –0.5>, p = 0.0157, showing a 
statistically significant improvement with HRO treatment 
compared to placebo (Fig. 3). Effects of age and sex 
as explanatory variables were investigated, but did not 
reveal any trends.
Analyses of changes in cytokine levels were underta-





















Adverse event (1) 
Unsatisfying response (1) 
Lost to follow-up (1) 
Adverse event (0) 
Unsatisfying response (0) 
Lost to follow-up (0) 
Screened patients 
(n= 94) 
Fig. 1. Flow diagram. HRO: herring roe oil.
Table II. Mean (SD) DLQI, PASI, BSA and PSGA scores, and 95% CI at baseline (week 0) and at week 26, change from baseline within 
group and comparison between groups. Last observation carried forward, intention-to-treat population. Mean (SD) measured CRP (mg/l) 
at baseline (week 0) and at week 26, change from baseline within group and comparison of log10 transformed CRP between groups
Visit
Herring roe oil Placebo Herring roe oil vs. placebo
n  Mean (SD) 95 % CI n Mean (SD) 95 % CI Estimate p-value 95 % CI
DLQI
  Week 0 32   8.7 (6.0) 6.6, 11 32 8.6 (5.2) 6.7, 11 . . .
  Week 26 32   6.8 (5.2) 5.0, 8.7 32 7.6 (6.0) 5.5, 9.8 . . .
  Change –1.9 (6.0) –4.1, 0.3 –1.0 (4.2) –2.5, 0.6 –0.9 0.47 –3.2, 1.5
PASI
  Week 0 32 6.1 (1.9) 5.4, 6.8 32 6.0 (1.7) 5.4, 6.6 . . .
  Week 26 32 4.4 (2.4) 3.5, 5.2 32 5.4 (2.7) 4.5, 6.4 . . .
  Change –1.8 (2.6) –2.7, –0.8 –0.6 (1.8) –1.3, 0.06 –1.1 0.045 –2.2, –0.03
BSA
  Week 0 32 7.3 (4.6) 5.6, 9.0 32 5.9 (3.1) 4.8, 7.0 . . .
  Week 26 32 5.8 (4.4) 4.2, 7.4 32 5.6 (4.2) 4.1, 7.2 . . .
  Change –1.6 (4.5) –3.2, 0.09 –0.3 (3.3) –1.5, 0.89 –0.5 0.57 –2.2, 1.2
PSGA
  Week 0 32 2.2 (0.5) 2.0, 2.4 32 2.1 (0.3) 2.0, 2.2 . . .
  Week 26 32 2.1 (0.7) 1.8, 2.3 32 2.1 (0.7) 1.8, 2.3 . . .
  Change –0.2 (0.7) –0.4, 0.1 –0.0 (0.7) –0.3, 0.2 . 0.70** .
C-reactive protein
  Week 0 29 6.1 (13.1) . 32 2.5 (2.3) . . . .
  Week 26 29 2.8 (2.9) . 32 2.4 (1.9) . . . .
  Change –3.3 (12.4) . –0.1 (1.9) . –0.03* 0.69 –0.19, 0.12
*Difference between herring roe oil and placebo in terms of log10 transformed C-reactive protein (CRP). **p-value from logistic regression model.
DLQI: Dermatological Life Quality Index; PASI: Psoriasis Area Severity Index; BSA: body surface area; PSGA: Physician’s Static Global Assessment; SD: standard 
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or increase in plasma cytokines from baseline to week 
26 were reviewed for all measured cytokines. The results 
for IL-17A and IL-23 are shown in Table III.
Safety 
Adverse events were recorded throughout the study and 
most patients experienced one or more adverse events 
in the 26-week study period, i.e. 94% of patients in the 
HRO group and 88% of patients in the placebo group. No 
serious adverse events were related to the administration 
of active treatment or placebo. 
Adverse events in skin and subcutaneous tissue 
were equally distributed between the active (44%) and 
the placebo (44%) group. Infections and infestations, 
primarily influenza like illness, pyrexia, influenza and 
nasopharyngitis, were evenly represented in the HRO 
and the placebo group.
In the active treatment group, 47% (n = 15) of pa-
tients experienced gastrointestinal events whereas 34% 
(n = 11) of patients in the placebo group experienced 
such events. The most frequently reported gastrointesti-
nal events were nausea (16%), diarrhoea (14%), upper 
abdominal pain (13%), flatulence (11%) and abdominal 
discomfort (9%) and their prevalence were similar in 
both study groups.
Musculoskeletal and connective tissue events origina-
ted from 16% (n = 5) of the patients treated with HRO and 
from 41% (n = 13) of the patients in the placebo group. 
DISCUSSION 
Ω-3 fatty acids as phospholipid esters have promise as 
adjunct treatment for plaque psoriasis (13, 14). The fatty 
acids have multiple roles in the skin, including maturation 
and differentiation of the stratum corneum, inhibition 
of proinflammatory eicosanoids and inhibition of pro-
inflammatory cytokines (tumour necrosis factor-alpha, 
interferon-gamma, and interleukin-12) (15).
Improvement of the mean PASI score in the HRO 
group compared to the control group at 26 weeks was 
demonstrated in this study. The effect was statistically 
significant in the ITT population and in a post-hoc ana-
lysis the effect was larger for patients with PASI over 5.5 
at baseline. Beneficial effects of treatment on PASI were 
not observed at the earlier visits (weeks 6, 12 and 18). 
Thus, the time to onset of efficacy was relatively long, 
which may be explained by the mechanism of action or 
the relatively mild nature of the disease in this particular 
patient population which had PASI < 10 at baseline.
Fig. 2. Psoriasis on the back of a patient in the active treatment 
group at week 26 (Psoriasis Area Severity Index: 0.7).
Fig. 3. Changes in Psoriasis Area Severity Index (PASI) score 
from baseline to week 26, in herring roe oil (HRO) and placebo 
treated patients with baseline PASI >5.5 (n = 31). Boxplot showing 
minimum, maximum, Q1 (25th percentile), Q3 (75th percentile), median 
(line) and mean (diamond) changes in both treatment groups. Patients in 
the sub-population were evenly distributed in the treatment groups, HRO 
n = 15; placebo n = 16.
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The impact of bioactive substances present in HRO 
on pro-inflammatory and anti-inflammatory mediators 
implicated in psoriasis, has been previously studied 
(16–19). Although the mechanism of action of HRO in 
psoriasis is unknown, lipid mediators derived from DHA 
have demonstrated anti-inflammatory effects in animal 
disease models, including suppression of IL-17A (20).
Statistically significant reductions of mean IL-17A and 
IL-23 plasma concentrations were not observed in this 
study when comparing the active treatment group and 
the control group from baseline to week 26. However, 
in the comparison of patient numbers with a decrease, 
no change or an increase in IL-23, significantly more 
patients in the HRO treated group had a decrease in 
plasma levels (n = 10) than an increase (n = 2) at week 26, 
indicating that IL-23 could be involved in the observed 
disease improvement.
Observations of clear reductions in plasma cytokine 
concentrations may not be expected in this study popu-
lation as the baseline concentrations of cytokines were 
low in a large proportion of the recruited patients. 
The treatment effect of HRO versus control in the total 
study population was a mean change in PASI score esti-
mated to –1.1 at week 26. As evidenced by the post-hoc 
analysis, which split the study population in halves of low 
and high baseline PASI scores, the measured efficacy was 
mediated by patients with baseline PASI scores above 5.5. 
The inclusion of patients with mild psoriasis could explain 
why secondary efficacy endpoints were not met. Firstly, 
PASI does not discriminate well when BSA is low (11). 
This is a simple consequence of the scoring methodology: 
If the PASI score assigned for each lesion characteristics 
(erythema, thickness, scaling and area) is 1, a relative re-
duction in either of these categories would not impact the 
PASI score unless lesions are completely cleared. Hence, 
measuring improvements at the lower end of the scale is 
inherently challenging (11). Secondly, the inability to mea-
sure significant effects in secondary endpoints may also 
be due to baseline values reflecting mild psoriasis. Mean 
baseline DLQI was < 9 and more than 80% of patients 
were categorised with PSGA ≤ 2. Furthermore, a delay in 
measurable improvements of patient assessed dermato-
logy life quality may be expected. Another reason is that 
the improvement at 26 weeks did not reach a sufficiently 
clinically meaningful level for the patients to be reflected 
in the patient reported outcome measures (21). 
Although this study targeted a psoriasis population ty-
pically treated with topical steroids, no attempt was made 
to compare the efficacy of HRO with steroid creams. 
HRO will never eliminate the need for local steroids, but 
it may be demonstrated as a useful long-term treatment 
alternative e.g. in cases where successful treatment with 
topical steroids is hampered by adverse reactions (22, 
23) or non-compliance (24). 
The study treatment was well tolerated and the preva-
lence of adverse events was as could be expected for a 
study of 26 weeks duration. Approximately 90% of the 
patients experienced one or more adverse events and 
there was no significant difference between the active 
treatment group and the placebo group. Although one 
patient withdrew from the study due to abdominal pain, 
nausea and gastritis, no serious adverse reactions oc-
curred.
According to the NICE guideline on assessment and 
management of psoriasis, systemic treatment would usu-
ally be recommended where severity score is BSA >10% 
or PASI >10 (25). This study demonstrates promise for 
HRO as a safe systemic treatment option in patients with 
psoriasis with PASI<10. More comprehensive studies 
are needed to establish whether the effect of HRO in the 
treatment of psoriasis vulgaris is clinically meaningful, 
investigating doses and defining a patient group with 
more severe disease in studies of longer duration.
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